title: Avastin hearing leads to more uncertainty over drug's future.
authors.forename: Merrill
authors.initials: M
authors.lastname: Goozner
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic / Q000379:methods; D018572:Disease-Free Survival; D017277:Drug Approval / Q000379:methods*; D004345:Drug Industry; D005260:Female; D006801:Humans; D019458:Insurance Coverage; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D035501:Uncertainty; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab